Johnson & Johnson licenses Vedanta’s bowel disease drug

SHARE Johnson & Johnson licenses Vedanta’s bowel disease drug

BOSTON — Johnson & Johnson has licensed a potential treatment for inflammatory bowel diseases from a company developing therapies that alter interactions between the immune system and microbes in the body.

J&J’s Janssen Pharmaceutical Cos. unit says Vedanta Biosciences of Boston could receive up to $241 million, including an upfront payment and additional ones if a medicine gets approved for a bowel disease such as ulcerative colitis or Crohn’s disease.

The experimental treatment, called VE202, hasn’t been studied in people but has shown effectiveness in animal tests. J&J will handle future testing.

The two companies could expand the partnership to treatments for additional conditions.

Johnson & Johnson, based in New Brunswick, New Jersey, is a leader in treatments for inflammatory bowel and other immune disorders, selling Remicade, Simponi and Stelara.

The Latest
The Packers’ victory makes it eight in a row in the rivalry and keeps them alive in the playoff race.
Congregants of the evangelical Willow Creek Community Church assembled just over 1,000 gift bags for inmates Sunday in the South Loop.
The Pro Football Hall of Famer has been at Jackson State since 2020. Sanders has guided the Tigers to consecutive Southwestern Athletic Conference titles.
Fields raced for a 56-yard touchdown in the first quarter, the fourth-longest run by a quarterback this season.